San Diego, CA (PRWEB) April 12, 2014
The International Society for Heart and Lung Transplantation (ISHLT) will announce today the one-year outcomes of the NOVEL lung trial, the first prospective and multicenter clinical trial designed to evaluate the safety of ex vivo lung perfusion (EVLP) as a platform for screening donor lungs that were initially deemed unusable prior to transplantation - a process that could potentially increase the number of usable lungs for patients awaiting transplantation.
EVLP is a method that maintains donor lungs at normal body temperature using a bloodless, nutrient-containing solution. The NOVEL trial determined in 84 test subjects that the outcomes following transplantation using EVLP were equal to outcomes of donors that used current standard criteria.
“We are excited with the results and believe that the NOVEL trial has helped in establishing the rationale to extend the donor pool and permit the acceptance of donor organs that might have otherwise been not transplanted,” said contributing expert Dr. Pablo G. Sanchez, Doctoral Research Fellow at the University of Maryland School of Medicine.
NOVEL findings with EVLP provide a glimpse into future directions in lung transplantation, concluding that successful outcomes may be achieved with lungs that otherwise would not have been considered for transplantation.
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit professional organization with more than 2,700 members from over 45 countries dedicated to improving the core of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. For more information, visit http://www.ishlt.org.